---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-004835"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:32:53.716274+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Q2 revenue up 83% to $396K; H1 test sales exceed full-year 2023

## Summary
- Q2 revenue $396K (+83% YoY); H1 revenue $567K (+55% YoY).
- Operating expenses down 24% YoY in Q2; targeting $10M annualized cost reductions.
- Cash $6.0M at June 30; closed $7M registered direct offering with up to $14.5M in milestone-linked warrants.
- Sold over 60,000 Nu.Q Vet Cancer Tests in H1 2024 (vs 58,000 full-year 2023); now available in 17 countries.
- Engaged PharmaVentures to advise on licensing deals for Nu.Q Cancer and Capture-PCR.

## SEC filing metadata
- accession: 0001477932-24-004835
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224004835/0001477932-24-004835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224004835/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-004835
- JSON: https://secwatch.observer/filing/0001477932-24-004835.json
- Plain text: https://secwatch.observer/filing/0001477932-24-004835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.